Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 7, 2021

Triall enters partnership to anchor Covid-19 data to blockchain

Triall will leverage LTO Network's blockchain technology and infrastructure to anchor the research data.

Dutch start-up Triall has entered a new partnership with local blockchain companies LTO Network and Sphereon to anchor Covid-19 research data.

The move is aimed to preserve the integrity and security of clinical trial data.

As agreed, Triall will leverage LTO Network’s blockchain technology and infrastructure to anchor the research data to the blockchain. The collaboration will start with a Covid-19 clinical trial and later can be expanded to other studies.

Triall CEO Hadil Es-Sbai said: “The ongoing Covid-19 crisis has sparked digital transformation across the pharmaceutical landscape.

“Our collaboration with LTO Network will pave the way for a range of innovative e-clinical software solutions supporting decentralised clinical trials.”

Clinical trials usually generate vast amounts of data and can continue for years. Some of the common challenges of such trials include increasing costs, recordkeeping failures, delays, and a lack of oversight.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

According to LTO Network, some of the blockchain properties such as decentralisation, security and privacy, will help in addressing such issues and consolidating the fragmented landscape of clinical trial stakeholders and software systems.

The use of blockchain will also prevent tampering and ensure transparency and integrity of research data.

LTO Network CEO Rick Schmitz said: “Together, we are building the world’s first clinical-trial software powered by the blockchain that will secure and streamline the development of a safe and affordable future in medicine.”

Triall focuses on creating a digital ecosystem of blockchain-integrated software solutions to facilitate the development of new vaccines and therapeutics during clinical trials. According to the company website, Triall’s software is created by clinical trial professionals.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU